CAJ | 학술논문

目的：研究α－硫辛酸治疗2型糖尿病早期肾病的临床疗效及安全性。方法选择2012年4月至2013年9月收治的2型糖尿病早期肾病患者132例，按入院顺序随机分成研究组和对照组，各66例。对照组患者使用替米沙坦治疗，研究组患者采用α－硫辛酸联合替米沙坦治疗。结果两组患者治疗前后空腹血糖（FPG）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL－C）、高密度脂蛋白胆固醇（HDL－ C）均无明显变化，组间比较，差异无统计学意义（ P>0.05）；研究组治疗后尿白蛋白( UAER )与血管内皮素－1( ET－1)均显著降低（ P<0.01），一氧化氮( NO )明显升高（ P<0.01），对照组治疗后与治疗前比较的差异无统计学意义（ P>0.05）；两组患者均无明显不良反应。结论α－硫辛酸治疗糖尿病早期肾病临床疗效显著，不良反应发生率低，安全可靠，值得临床推广。
목적：연구α－류신산치료2형당뇨병조기신병적림상료효급안전성。방법선택2012년4월지2013년9월수치적2형당뇨병조기신병환자132례，안입원순서수궤분성연구조화대조조，각66례。대조조환자사용체미사탄치료，연구조환자채용α－류신산연합체미사탄치료。결과량조환자치료전후공복혈당（FPG）、삼선감유（TG）、총담고순（TC）、저밀도지단백담고순（LDL－C）、고밀도지단백담고순（HDL－ C）균무명현변화，조간비교，차이무통계학의의（ P>0.05）；연구조치료후뇨백단백( UAER )여혈관내피소－1( ET－1)균현저강저（ P<0.01），일양화담( NO )명현승고（ P<0.01），대조조치료후여치료전비교적차이무통계학의의（ P>0.05）；량조환자균무명현불량반응。결론α－류신산치료당뇨병조기신병림상료효현저，불량반응발생솔저，안전가고，치득림상추엄。
Objective To study tbe clinical effect and safety of alpba lipoic acid in tbe treatment of early type 2 diabetic nepbropatby (T2DN). Methods Totally 132 cases of early T2DN in tbe bospital from April 2012 to September 2013 were selected and randomly divided into tbe study group and tbe control group according to tbe admission serial number,66 cases in eacb group. Tbe control group used tbe telmisartan treatment,wbile tbe study group adopted tbe tberapy of alpba lipoic acid combined witb telmisartan. Results FPG, TG,TC,LDL-C,HDL-C before and after treatment bad no significant cbanges in tbe two groups and tbe differences between tbe two groups bad no statistical significance ( P > 0. 05);UAER and ET-1 after treatment in tbe study group were decreased significantly ( P < 0. 01),wbereas NO increased significantly( P < 0. 01);but wbicb after treatment in tbe control group bad no statistically signifi-cant differences compared witb before treatment( P > 0. 05);no obvious adverse reactions occurred in tbe two groups. Conclusion Al-pba lipoic acid bas significantly clinical effect and low occurrence rate of adverse reactions,it is safe and reliable for treating early T2DN,and is wortby of clinical promotion.